While mRNA vaccines from Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) had 95% efficacy in Phase 3 clinical trials, their effectiveness in the real world has dropped with the rise of the Delta variant.  As a result, breakthrough infections have grown more common in people who have received two doses of mRNA vaccines. Ultimately, full vaccination may require…